Cargando…

Hyperbaric oxygen therapy as a complementary treatment in neuroblastoma — a narrative review

Neuroblastoma is the most frequently diagnosed cancer during the first year of life. This neoplasm originates from neural crest cells derived from the sympathetic nervous system, adrenal medulla, or paraspinal ganglia. The clinical presentation can vary from an asymptomatic mass to symptoms resultin...

Descripción completa

Detalles Bibliográficos
Autores principales: Alpuim Costa, Diogo, Gonçalves-Nobre, J. Guilherme, Sampaio-Alves, Mafalda, Guerra, Nuno, Arana Ribeiro, Joana, Espiney Amaro, Carla
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10562625/
https://www.ncbi.nlm.nih.gov/pubmed/37823059
http://dx.doi.org/10.3389/fonc.2023.1254322
_version_ 1785118169109626880
author Alpuim Costa, Diogo
Gonçalves-Nobre, J. Guilherme
Sampaio-Alves, Mafalda
Guerra, Nuno
Arana Ribeiro, Joana
Espiney Amaro, Carla
author_facet Alpuim Costa, Diogo
Gonçalves-Nobre, J. Guilherme
Sampaio-Alves, Mafalda
Guerra, Nuno
Arana Ribeiro, Joana
Espiney Amaro, Carla
author_sort Alpuim Costa, Diogo
collection PubMed
description Neuroblastoma is the most frequently diagnosed cancer during the first year of life. This neoplasm originates from neural crest cells derived from the sympathetic nervous system, adrenal medulla, or paraspinal ganglia. The clinical presentation can vary from an asymptomatic mass to symptoms resulting from local invasion and/or spread of distant disease spread. The natural history of neuroblastoma is highly variable, ranging from relatively indolent biological behavior to a high-risk clinical phenotype with a dismal prognosis. Age, stage, and biological features are important prognostic risk stratification and treatment assignment prognostic factors. The multimodal therapy approach includes myeloablative chemotherapy, radiotherapy, immunotherapy, and aggressive surgical resection. Hyperbaric oxygen therapy (HBOT) has been proposed as a complementary measure to overcome tumor hypoxia, which is considered one of the hallmarks of this cancer treatment resistance. This article aims to review the relevant literature on the neuroblastoma pathophysiology, clinical presentation, and different biological and genetic profiles, and to discuss its management, focusing on HBOT.
format Online
Article
Text
id pubmed-10562625
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-105626252023-10-11 Hyperbaric oxygen therapy as a complementary treatment in neuroblastoma — a narrative review Alpuim Costa, Diogo Gonçalves-Nobre, J. Guilherme Sampaio-Alves, Mafalda Guerra, Nuno Arana Ribeiro, Joana Espiney Amaro, Carla Front Oncol Oncology Neuroblastoma is the most frequently diagnosed cancer during the first year of life. This neoplasm originates from neural crest cells derived from the sympathetic nervous system, adrenal medulla, or paraspinal ganglia. The clinical presentation can vary from an asymptomatic mass to symptoms resulting from local invasion and/or spread of distant disease spread. The natural history of neuroblastoma is highly variable, ranging from relatively indolent biological behavior to a high-risk clinical phenotype with a dismal prognosis. Age, stage, and biological features are important prognostic risk stratification and treatment assignment prognostic factors. The multimodal therapy approach includes myeloablative chemotherapy, radiotherapy, immunotherapy, and aggressive surgical resection. Hyperbaric oxygen therapy (HBOT) has been proposed as a complementary measure to overcome tumor hypoxia, which is considered one of the hallmarks of this cancer treatment resistance. This article aims to review the relevant literature on the neuroblastoma pathophysiology, clinical presentation, and different biological and genetic profiles, and to discuss its management, focusing on HBOT. Frontiers Media S.A. 2023-09-26 /pmc/articles/PMC10562625/ /pubmed/37823059 http://dx.doi.org/10.3389/fonc.2023.1254322 Text en Copyright © 2023 Alpuim Costa, Gonçalves-Nobre, Sampaio-Alves, Guerra, Arana Ribeiro and Espiney Amaro https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Alpuim Costa, Diogo
Gonçalves-Nobre, J. Guilherme
Sampaio-Alves, Mafalda
Guerra, Nuno
Arana Ribeiro, Joana
Espiney Amaro, Carla
Hyperbaric oxygen therapy as a complementary treatment in neuroblastoma — a narrative review
title Hyperbaric oxygen therapy as a complementary treatment in neuroblastoma — a narrative review
title_full Hyperbaric oxygen therapy as a complementary treatment in neuroblastoma — a narrative review
title_fullStr Hyperbaric oxygen therapy as a complementary treatment in neuroblastoma — a narrative review
title_full_unstemmed Hyperbaric oxygen therapy as a complementary treatment in neuroblastoma — a narrative review
title_short Hyperbaric oxygen therapy as a complementary treatment in neuroblastoma — a narrative review
title_sort hyperbaric oxygen therapy as a complementary treatment in neuroblastoma — a narrative review
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10562625/
https://www.ncbi.nlm.nih.gov/pubmed/37823059
http://dx.doi.org/10.3389/fonc.2023.1254322
work_keys_str_mv AT alpuimcostadiogo hyperbaricoxygentherapyasacomplementarytreatmentinneuroblastomaanarrativereview
AT goncalvesnobrejguilherme hyperbaricoxygentherapyasacomplementarytreatmentinneuroblastomaanarrativereview
AT sampaioalvesmafalda hyperbaricoxygentherapyasacomplementarytreatmentinneuroblastomaanarrativereview
AT guerranuno hyperbaricoxygentherapyasacomplementarytreatmentinneuroblastomaanarrativereview
AT aranaribeirojoana hyperbaricoxygentherapyasacomplementarytreatmentinneuroblastomaanarrativereview
AT espineyamarocarla hyperbaricoxygentherapyasacomplementarytreatmentinneuroblastomaanarrativereview